# Aldeyra Therapeutics, Inc. (ALDX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Aldeyra Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ALDX/mda/fy2025/): filed 2026-02-27; accession 0001193125-26-083012 (https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ALDX/mda/fy2024/): filed 2025-02-28; accession 0000950170-25-030102 (https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm)
- [FY 2023 MD&A](/company/ALDX/mda/fy2023/): filed 2024-03-07; accession 0000950170-24-027933 (https://www.sec.gov/Archives/edgar/data/1341235/000095017024027933/aldx-20231231.htm)
- [FY 2022 MD&A](/company/ALDX/mda/fy2022/): filed 2023-03-09; accession 0000950170-23-006998 (https://www.sec.gov/Archives/edgar/data/1341235/000095017023006998/aldx-20221231.htm)
- [FY 2021 MD&A](/company/ALDX/mda/fy2021/): filed 2022-03-17; accession 0000950170-22-004111 (https://www.sec.gov/Archives/edgar/data/1341235/000095017022004111/aldx-20211231.htm)

Back to /company/ALDX/